Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15304623Application Date: 2015-04-16
-
Publication No.: US09957251B2Publication Date: 2018-05-01
- Inventor: Takaharu Hirayama , Jun Fujimoto , Douglas Robert Cary , Masanori Okaniwa , Yasuhiro Hirata
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JP2014-086927 20140418
- International Application: PCT/JP2015/061660 WO 20150416
- International Announcement: WO2015/159938 WO 20151022
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D401/14 ; C07D405/14 ; C07D413/14 ; C07D491/08 ; A61K31/4439 ; A61K31/444 ; A61K31/4545 ; A61K31/4704 ; A61K31/4725 ; A61K31/496 ; A61K31/4985 ; A61K31/499 ; A61K31/5377 ; A61K31/5386 ; A61K31/541 ; A61K31/553 ; C07D409/04 ; C07D409/14 ; C07D417/04 ; C07D417/14 ; C07D471/04 ; C07D487/04 ; C07D487/08 ; C07D491/107 ; C07D498/08 ; C07D213/64
Abstract:
The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.
Public/Granted literature
- US20170044132A1 HETEROCYCLIC COMPOUND Public/Granted day:2017-02-16
Information query
